View Older Stories View More Recent Stories
-
Eli Lilly, Novo Nordisk shares fall as Ozempic, Wegovy tied to rare cases of vision loss
-
Ozempic Linked to Rare Cases of Vision Loss in Harvard Study - Bloomberg (NVO)
-
Pharma selloff overdone: JPMorgan
-
Novo Nordisk (NVO) call put ratio 2.1 calls to 1 put after USAToday editorial
-
Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put with focus on August 140 calls
-
Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices
-
Biden Says Novo Nordisk (NVO) Must Cut Ozempic, Wegovy Prices
-
Novo Nordisk (NVO) call put ratio 2.7 calls to 1 put with focus on December 150 calls
-
2seventy bio (TSVT) Completes $40M Deal to Sell Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk (NVO)
-
Novo Nordisk (NVO) stops ocedurenone Clarion-CKD trial, will recognize DKK 5.7B impairment charge
-
Midday movers: Nvidia, Carnival Rise; SolarEdge, Pool fall
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO)
-
Novo Nordisk (NVO) Invests $4.1 Billion In North Carolina Facility - Bloomberg
-
Novo Nordisk (NVO): Ozempic Phase 3 Trial Meets Primary Endpoint in Kidney Disease
-
Novo Nordisk (NVO) call put ratio 4.5 calls to 1 put
-
Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) call put ratio 3 calls to 1 put.
-
Novo Nordisk (NVO) announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease
-
BofA lifts Novo Nordisk price target on EPS upside potential, upcoming pipeline data
-
Senate Panel Plans to Vote on Subpoena for Novo Nordisk (NVO) President - Bloomberg
-
Novo Nordisk (NVO) PT Raised to $160 at Argus
-
Buy the dip in this major pharma stock - Citi
-
Cabot Wealth shares top 10 stocks picks for this week
-
These 4 stocks are just added to Argus top picks list
